DaehanPharmaceutical (023910) Financial Statements

OverviewFinancialsChecksFilings

In fiscal year 2025, DaehanPharmaceutical (023910) reported revenue of 208.6 billion KRW.

Income Statement

YearRevenueOp ProfitNet IncomeSource
2025208.6 billion KRW31.2 billion KRW27.6 billion KRW[source]
2024204.2 billion KRW38.1 billion KRW33.8 billion KRW[source]
2023195.9 billion KRW35.8 billion KRW28.4 billion KRW[source]
2022184.3 billion KRW33.0 billion KRW25.0 billion KRW[source]
2021171.5 billion KRW29.1 billion KRW22.7 billion KRW[source]

Balance Sheet

YearTotal AssetsTotal LiabilitiesTotal EquitySource
2025347.7 billion KRW47.4 billion KRW300.2 billion KRW[source]
2024324.4 billion KRW48.4 billion KRW276.0 billion KRW[source]
2023294.3 billion KRW46.3 billion KRW248.0 billion KRW[source]
2022277.0 billion KRW51.6 billion KRW225.4 billion KRW[source]
2021272.5 billion KRW69.7 billion KRW202.8 billion KRW[source]
Financials & Filings: DART (traceable by receipt number) · Prices: Financial Services Commission · Data Sources · Last checked: 2026-08-29 · About · Delisting market cap threshold: KOSPI 5B KRW / KOSDAQ 4B KRW (per listing rules) · This page provides factual information, not investment advice